Robert De Jonge

Robert de Jonge is the Head of Corporate Development of Mestag Therapeutics. Robert has broad background in business and corporate development in biotech. He joined Mestag from Cellinta, where he was the Head of Corporate Development. Previously, he was the Head of Business Development at Tusk Therapeutics, an immuno oncology company developing antibody therapeutics for the treatment of cancer. At Tusk, he was responsible for the company’s business development activities. He was closely involved in the sale of Tusk to Roche (€655m, €70m upfront). Robert also served as the Chief Executive Officer of Black Belt Therapeutics; an oncology company focused on targeting the stress response pathways in cancer. Earlier in his career, he worked as the Head of Contract Research for reMYND, a biotech company focused on the development of small molecule therapeutics for the treatment of Alzheimer’s, Parkinson’s and Diabetes. He also worked as an investment analyst at M Ventures, Merck KGaA’s corporate venture capital arm. He holds an MSc in molecular biology and business economics from Leiden University and Delft University of Technology in the Netherlands.